{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-136384","form_type":"8-K","ticker":"LRMR","cik":"0001374690","company_name":"Larimar Therapeutics, Inc.","filed_at":"2024-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.284572+00:00","generated_at":"2026-05-29T02:50:09.729799+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Larimar reports positive OLE data: FXN up to 30% of healthy in buccal cells at Day 90; BLA filing targeted 2H 2025","bullets":["Mean change from baseline of 1.32 pg/μg in buccal cells and 9.28 pg/μg in skin cells at Day 90.","Tissue FXN increased from 15% to 30% of healthy volunteers in buccal cells and 16% to 72% in skin cells.","Daily 25 mg nomlabofusp generally well tolerated; two SAEs resolved within 24 hours; 50 mg dose escalation initiated.","BLA submission for potential accelerated approval targeted for 2H 2025; cash runway of $203.7M into Q2 2026.","Early trends towards improvement in mFARS, ADL, and other clinical outcomes observed at Day 90."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-136384","json":"https://secwatch.observer/filing/0000950170-24-136384.json","markdown":"https://secwatch.observer/filing/0000950170-24-136384.md","text":"https://secwatch.observer/filing/0000950170-24-136384.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374690/000095017024136384/0000950170-24-136384-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374690/000095017024136384/lrmr-20241216.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T02:50:09.729799+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}